Statin use after acute myocardial infarction by patient complexity are the rates right?

Medical Care

Volumn 53, Issue 4, 2015, Pages 324-331

  Brooks, John M ^a   Cook, Elizabeth ^b   Chapman, Cole G ^a   Schroeder, Mary C ^b   Chrischilles, Elizabeth A ^b   Schneider, Kathleen M ^c   Kulchaitanaroaj, Puttarin ^d   Robinson, Jennifer ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Associates LLC   (United States)

^d BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

adverse events; costs; effectiveness; geographic variation; instrumental variables; statins; survival

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; AFRICAN AMERICAN; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICARE; MUSCLE DISEASE; PRESCRIPTION; PRIORITY JOURNAL; SURVIVAL RATE; VERY ELDERLY; ACUTE DISEASE; COMORBIDITY; DRUG UTILIZATION; INSURANCE; MYOCARDIAL INFARCTION; PRACTICE GUIDELINE; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; COMORBIDITY; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; UNITED STATES;

EID: 84925934085     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000322     Document Type: Article

References (42)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2000; 36: 970-1056
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article-A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-1900
3. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk REduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 Update-A Guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458-2473
4. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J. 2008; 29: 2909-2945
5. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003; 24: 28-66
6. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33: 2569-2619
7. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 25(Suppl 2): S1-S45
8. Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65, 396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010; 160: 1130-1136. e1-3
9. Lewis WR, Ellrodt G, Peterson E, et al. Trends in the use of evidencebased treatments for coronary artery disease among women and the elderly: findings from the get with the Guidelines Quality-Improvement Program. Circulation. 2009; 2: 633-641
10. Zuckerman IH, Yin X, Rattinger GB, et al. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J Am Geriatr Soc. 2012; 60: 1854-1861
11. Brooks JM, Cook EA, Chapman CG, et al. Statin use following acute myocardial infarction by patient complexity: evidence of effective care? Med Care. 2014; 52: S37-S44
12. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Affairs. 2012; 31: 2276-2285
13. National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002; 106: 3143-3421
14. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006; 119: 676-683
15. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006; 98: 1405-1408
16. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-2016
17. Shepherd J, Kastelein JJP, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008; 51: 1448-1454
18. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-2261
19. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013; 173: 1308-1317
20. Zhang HB, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings a cohort study. Ann Intern Med. 2013; 158: 526-534
21. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011; 10: 373-387
22. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008; 8: 373-418
23. Florentin M, Elisaf MS. Simvastatin interactions with other drugs. Expert Opin Drug Saf. 2012; 11: 439-444
24. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006; 97: 61C-68C
25. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br Med J. 2010; 340: 12
26. Wennberg JE. Which rate is right? N Engl J Med. 1986; 315: 810-815
27. Phelps CE. Health Economics. 2nd ed., Reading, Massachusetts: Addison-Wesley; 1997
28. Park TR, Brooks JM, Chrischilles EA, et al. Estimating the effect of treatment rate changes when treatment benefits are heterogeneous: Antibiotics and otitis media. Value Health. 2008; 11: 304-314
29. Brooks JM, McClellan M, Wong HS. The marginal benefits of invasive treatments for acute myocardial infarction: does insurance coverage matter? Inquiry J Health Car. 2000; 37: 75-90
30. Harris KM, Remler DK. Who is the marginal patient? Understanding instrumental variables estimates of treatment effects. Health Serv Res. 1998; 33: 1337-1360
31. McClellan M, Newhouse JP. Instrumental variables analysis applications in health services research-A special supplement to HSR-overview of supplement issue. Health Serv Res. 2000; 35: 1061-1069
32. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-Analysis. Br Med J. 2003; 326: 1423-1427
33. Fang G, Brooks JM, Chrischilles EA. A new method to measure geographic variation in prescription use and its implications for comparative effectiveness research. Med Care. 2010; 40: 710-717
34. Fang G, Brooks JM, Chrischilles EA. Comparison of instrumental variable analysis using a new instrument with risk adjustment methods to reduce confounding by indication. Am J Epidemiol. 2012; 175: 1142-1151
35. Brooks JM, Chrischilles EA, Landrum MB, et al. Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012; 2012: 127854
36. Klabunde, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267
37. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data. Med Care. 2002; 40: IV26-IV35
38. Wooldridge JM. Introductory Econometrics: A Modern Approach Chapter 4. Mason, OH: Thomson South-Western; 2003
39. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681
40. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278
41. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1231-1239
42. Collins R, Armitage J, Parish S, et al. Heart Protection Study C. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22